Tcg Fluent Pharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for TCG FLUENT PHARMA, and when can generic versions of TCG FLUENT PHARMA drugs launch?
TCG FLUENT PHARMA has one approved drug.
There are two US patents protecting TCG FLUENT PHARMA drugs.
There are eight patent family members on TCG FLUENT PHARMA drugs in twelve countries and five supplementary protection certificates in five countries.
Summary for Tcg Fluent Pharma
| International Patents: | 8 |
| US Patents: | 2 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Tcg Fluent Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tcg Fluent Pharma | FLOLIPID | simvastatin | SUSPENSION;ORAL | 206679-001 | Apr 21, 2016 | RX | Yes | No | 9,597,289 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Tcg Fluent Pharma | FLOLIPID | simvastatin | SUSPENSION;ORAL | 206679-001 | Apr 21, 2016 | RX | Yes | No | 10,300,041 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Tcg Fluent Pharma | FLOLIPID | simvastatin | SUSPENSION;ORAL | 206679-002 | Apr 21, 2016 | RX | Yes | Yes | 10,300,041 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Tcg Fluent Pharma Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Spain | 2385752 | ⤷ Try a Trial |
| Austria | E552825 | ⤷ Try a Trial |
| Japan | 2009534459 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Tcg Fluent Pharma Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0720599 | SPC/GB05/010 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: EZETIMIBE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN COMBINATION WITH SIMVASTATIN; REGISTERED: DE 58874.00.00 20040402; DE 58874.01.00 20040402; DE 58874.02.00 20040402; DE 58874.03.00 20040402; DE 58878.00.00 20040402; DE 58878.01.00 20040402; DE 58878.02.00 20040402; DE 58878.03.00 20040402; DE 58866.00.00 20040402; DE 58866.01.00 20040402; DE 58866.02.00 20040402; DE 58866.03.00 20040402; DE 58870.00.00 20040402; DE 58870.01.00 20040402; DE 58870.02.00 20040402; DE 58870.03.00 20040402; UK PL 19945/0003 20041118; UK PL 19945/0004 20041118; UK PL 19945/0005 20041118; UK PL 19945/0006 20041118; UK PL 19945/0007 20041118; UK PL 19945/0008 20041118; UK PL 19945/0009 200411 |
| 0720599 | 05C0040 | France | ⤷ Try a Trial | PRODUCT NAME: EZETIMIBE; SIMVASTATINE; NAT. REGISTRATION NO/DATE: NL 31849 20050728; FIRST REGISTRATION: DE - 58 878 00 00 20040402 |
| 0720599 | C300172 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN SIMVASTATINE; NAT. REGISTRATION NO/DATE: RVG 30927RVG 30928RVG 30929RVG 30930 2004221122; FIRST REGISTRATION: 58874.00.0058874.01.0058874.02.0058874.03.0058878.00.0058878.01.0058878.02.0058878.03.0058866.00.0058866.01.0058866.02.0058866.03.0058870.00.0058870.01.0058870.02.0058870.03.00 2004020402 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
